A detailed history of Tower Research Capital LLC (Trc) transactions in Novo Nordisk A S stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,933 shares of NVO stock, worth $867,846. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,933
Previous 17,022 41.65%
Holding current value
$867,846
Previous $2.43 Million 51.34%
% of portfolio
0.03%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.07 - $145.42 $844,087 - $1.03 Million
-7,089 Reduced 41.65%
9,933 $1.18 Million
Q2 2024

Aug 13, 2024

BUY
$122.71 - $146.91 $989,042 - $1.18 Million
8,060 Added 89.94%
17,022 $2.43 Million
Q1 2024

May 15, 2024

BUY
$102.11 - $135.92 $511,060 - $680,279
5,005 Added 126.48%
8,962 $1.15 Million
Q4 2023

Feb 13, 2024

BUY
$87.78 - $105.45 $166,782 - $200,355
1,900 Added 92.37%
3,957 $409,000
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $22,007 - $48,288
242 Added 13.33%
2,057 $187,000
Q2 2023

Aug 14, 2023

BUY
$155.98 - $172.65 $252,063 - $279,002
1,616 Added 812.06%
1,815 $293,000
Q1 2023

May 09, 2023

BUY
$132.34 - $159.14 $16,410 - $19,733
124 Added 165.33%
199 $32,000
Q4 2022

Feb 10, 2023

SELL
$102.55 - $135.33 $803,069 - $1.06 Million
-7,831 Reduced 99.05%
75 $10,000
Q3 2022

Nov 10, 2022

BUY
$95.28 - $116.93 $365,684 - $448,777
3,838 Added 94.35%
7,906 $788,000
Q2 2022

Aug 15, 2022

BUY
$103.24 - $121.81 $49,348 - $58,225
478 Added 13.31%
4,068 $453,000
Q1 2022

May 12, 2022

SELL
$93.1 - $112.54 $534,207 - $645,754
-5,738 Reduced 61.51%
3,590 $398,000
Q4 2021

Feb 14, 2022

BUY
$95.88 - $117.08 $891,204 - $1.09 Million
9,295 Added 28166.67%
9,328 $1.05 Million
Q3 2021

Nov 15, 2021

BUY
$84.42 - $106.62 $2,785 - $3,518
33 New
33 $3,000
Q2 2021

Aug 16, 2021

SELL
$67.66 - $84.76 $380,925 - $477,198
-5,630 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$67.06 - $75.82 $120,775 - $136,551
1,801 Added 47.04%
5,630 $380,000
Q4 2020

Feb 16, 2021

SELL
$63.89 - $73.8 $22,808 - $26,346
-357 Reduced 8.53%
3,829 $267,000
Q3 2020

Nov 16, 2020

BUY
$63.69 - $70.22 $253,231 - $279,194
3,976 Added 1893.33%
4,186 $291,000
Q2 2020

Aug 13, 2020

SELL
$58.54 - $67.94 $1,170 - $1,358
-20 Reduced 8.7%
210 $14,000
Q1 2020

May 15, 2020

BUY
$49.46 - $64.78 $11,375 - $14,899
230 New
230 $14,000
Q4 2019

Feb 07, 2020

SELL
$49.86 - $58.26 $17,600 - $20,565
-353 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$47.54 - $53.43 $16,781 - $18,860
353 New
353 $18,000
Q2 2019

Aug 13, 2019

SELL
$46.79 - $52.47 $120,811 - $135,477
-2,582 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$46.36 - $52.63 $118,867 - $134,943
2,564 Added 14244.44%
2,582 $135,000
Q4 2018

Feb 14, 2019

BUY
$41.54 - $47.25 $747 - $850
18 New
18 $1,000
Q2 2018

Aug 15, 2018

SELL
$44.29 - $50.42 $15,678 - $17,848
-354 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$48.49 - $58.14 $17,165 - $20,581
354 New
354 $17,000
Q4 2017

Feb 09, 2018

SELL
$47.53 - $53.73 $68,158 - $77,048
-1,434 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$41.15 - $49.22 $59,009 - $70,581
1,434
1,434 $69,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.